These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 20870094)

  • 1. Exenatide in type 2 diabetes.
    Verzegnassi F; Chinello M
    Lancet; 2010 Sep; 376(9746):1052-3; author reply 1053. PubMed ID: 20870094
    [No Abstract]   [Full Text] [Related]  

  • 2. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
    Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
    [No Abstract]   [Full Text] [Related]  

  • 3. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress.
    Bunck MC; Cornér A; Eliasson B; Heine RJ; Shaginian RM; Wu Y; Yan P; Smith U; Yki-Järvinen H; Diamant M; Taskinen MR
    Atherosclerosis; 2010 Sep; 212(1):223-9. PubMed ID: 20494360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longacting exenatide in diabetes: DURATION-3.
    Misra A; Joshi S
    Lancet; 2010 Jun; 375(9733):2198-9. PubMed ID: 20609957
    [No Abstract]   [Full Text] [Related]  

  • 5. Exenatide added to insulin. Beware the potentially serious adverse effects of exenatide.
    Prescrire Int; 2013 Jun; 22(139):151. PubMed ID: 23885352
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes?
    Ann Intern Med; 2005 Oct; 143(8):I30. PubMed ID: 16230718
    [No Abstract]   [Full Text] [Related]  

  • 8. [Blood sugar and pounds down, hardly hypoglycemias. New generation of antidiabetics ante portas].
    Einecke D
    MMW Fortschr Med; 2006 Aug; 148(35-36):4-6, 8, 10. PubMed ID: 16995353
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK.
    Beaudet A; Palmer JL; Timlin L; Wilson B; Bruhn D; Boye KS; Lloyd A
    J Med Econ; 2011; 14(3):357-66. PubMed ID: 21563878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide may aggravate moderate diabetic renal impairment: a case report.
    Johansen OE; Whitfield R
    Br J Clin Pharmacol; 2008 Oct; 66(4):568-9. PubMed ID: 18537959
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study.
    Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M
    Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exenatide once weekly in type 2 diabetes.
    Scheen AJ
    Lancet; 2008 Oct; 372(9645):1197-8. PubMed ID: 18782642
    [No Abstract]   [Full Text] [Related]  

  • 13. Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
    Pawaskar MD; Blickensderfer AL; Hoogwerf BJ; Quimbo R; Wade R
    J Med Econ; 2011; 14(6):705-8. PubMed ID: 21892855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exenatide (Byetta) for type 2 diabetes.
    Med Lett Drugs Ther; 2005 Jun; 47(1210):45-6. PubMed ID: 15933616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualised incretin-based treatment for type 2 diabetes.
    Nauck MA; Meier JJ
    Lancet; 2010 Aug; 376(9739):393-4. PubMed ID: 20580425
    [No Abstract]   [Full Text] [Related]  

  • 16. Exenatide for once-weekly administration.
    Drug Ther Bull; 2012 Jul; 50(7):78-80. PubMed ID: 22789767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA; Boye KS; Yurgin N; Valentine WJ; Roze S; McKendrick J; Tucker DM; Foos V; Palmer AJ
    Curr Med Res Opin; 2007 Mar; 23(3):609-22. PubMed ID: 17355742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.
    Pawaskar M; Tuttle KR; Li Q; Best JH; Anderson PW
    Ann Pharmacother; 2014 May; 48(5):571-6. PubMed ID: 24497624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time for clinically relevant comparative effectiveness studies in type 2 diabetes.
    Nathan DM
    Ann Intern Med; 2011 Jan; 154(2):131-2. PubMed ID: 21135287
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.